Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 73

1.

The HER family and cancer: emerging molecular mechanisms and therapeutic targets.

Sergina NV, Moasser MM.

Trends Mol Med. 2007 Dec;13(12):527-34. Epub 2007 Nov 5. Review.

2.

Epidermal growth factor receptor family tyrosine kinases as signal integrators and therapeutic targets.

Barnes CJ, Kumar R.

Cancer Metastasis Rev. 2003 Dec;22(4):301-7. Review.

PMID:
12884907
3.

Critical update and emerging trends in epidermal growth factor receptor targeting in cancer.

Baselga J, Arteaga CL.

J Clin Oncol. 2005 Apr 10;23(11):2445-59. Epub 2005 Mar 7. Review. Erratum in: J Clin Oncol. 2005 Sep 1;23(25):6281.

PMID:
15753456
4.
5.

The diverse signaling network of EGFR, HER2, HER3 and HER4 tyrosine kinase receptors and the consequences for therapeutic approaches.

Zaczek A, Brandt B, Bielawski KP.

Histol Histopathol. 2005 Jul;20(3):1005-15. Review.

PMID:
15944951
6.

The ErbB/HER receptor protein-tyrosine kinases and cancer.

Roskoski R Jr.

Biochem Biophys Res Commun. 2004 Jun 18;319(1):1-11. Review.

PMID:
15158434
7.

Ligand-triggered resistance to molecular targeted drugs in lung cancer: roles of hepatocyte growth factor and epidermal growth factor receptor ligands.

Yano S, Takeuchi S, Nakagawa T, Yamada T.

Cancer Sci. 2012 Jul;103(7):1189-94. doi: 10.1111/j.1349-7006.2012.02279.x. Epub 2012 May 9. Review.

8.
9.

Redox regulation of epidermal growth factor receptor signaling through cysteine oxidation.

Truong TH, Carroll KS.

Biochemistry. 2012 Dec 18;51(50):9954-65. doi: 10.1021/bi301441e. Epub 2012 Dec 5. Review.

10.

EGFR ligands and their signaling scissors, ADAMs, as new molecular targets for anticancer treatments.

Kataoka H.

J Dermatol Sci. 2009 Dec;56(3):148-53. doi: 10.1016/j.jdermsci.2009.10.002. Epub 2009 Nov 6. Review.

PMID:
19896805
11.
12.

Clinical implications of the ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer.

Lafky JM, Wilken JA, Baron AT, Maihle NJ.

Biochim Biophys Acta. 2008 Apr;1785(2):232-65. doi: 10.1016/j.bbcan.2008.01.001. Epub 2008 Feb 7. Review.

PMID:
18291115
13.

The impact of gefitinib on epidermal growth factor receptor signaling pathways in cancer.

Averbuch SD.

Clin Lung Cancer. 2003 Sep;5 Suppl 1:S5-S10. Review.

PMID:
14641988
14.

[HER-ErbB family of receptors and their ligands: mechanisms of activation, signals and deregulation in cancer].

L'Allemain G.

Bull Cancer. 2003 Nov;90 Spec No:S179-85. Review. French.

PMID:
14763137
15.

Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.

Harding J, Burtness B.

Drugs Today (Barc). 2005 Feb;41(2):107-27. Review.

PMID:
15821783
16.

Targeting epidermal growth factor receptor signaling: early results and future trends in oncology.

Lage A, Crombet T, González G.

Ann Med. 2003;35(5):327-36. Review.

PMID:
12952019
17.

[Anti-HER2 antibody and small-molecule tyrosine kinase inhibitor therapy targeting EGFR signal pathway].

Yamashiro H, Toi M.

Gan To Kagaku Ryoho. 2009 Jul;36(7):1067-71. Review. Japanese.

PMID:
19620793
18.

Targeting ErbB receptors in high-grade glioma.

Berezowska S, Schlegel J.

Curr Pharm Des. 2011;17(23):2468-87. Review.

PMID:
21827413
19.

Protein kinases as targets for anticancer agents: from inhibitors to useful drugs.

Fabbro D, Ruetz S, Buchdunger E, Cowan-Jacob SW, Fendrich G, Liebetanz J, Mestan J, O'Reilly T, Traxler P, Chaudhuri B, Fretz H, Zimmermann J, Meyer T, Caravatti G, Furet P, Manley PW.

Pharmacol Ther. 2002 Feb-Mar;93(2-3):79-98. Review.

PMID:
12191602
20.

Targeting HER1/EGFR: a molecular approach to cancer therapy.

Arteaga C.

Semin Oncol. 2003 Jun;30(3 Suppl 7):3-14. Review.

PMID:
12840796
Items per page

Supplemental Content

Write to the Help Desk